Navigation Links
EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors

EUSA Pharma Announces the Appointment of Stephen A. Stamp to... -- OXFORD, England and LANGHORNE, Pennsylvania, September 1, 2010 /PRNewswire/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Personnel Announcements Click to view news release full screen  

EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors


OXFORD, England and LANGHORNE, Pennsylvania, September 1, 2010 /PRNewswire/ -- EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced the appointment of Stephen A. Stamp to the company's Board as an independent Non-Executive Director.

Mr Stamp has extensive experience of the specialty pharmaceutical sector having previously held Board-level roles at Xanodyne Pharmaceuticals Inc. and Shire Pharmaceuticals Plc, and most recently as Chief Financial Officer of K-V Pharmaceutical Company. Mr Stamp has considerable financial expertise developed during a career spanning over 25 years, including more than 10 years in corporate finance and investment banking. He is an Associate Member of the Institute of Chartered Accountants.

"I want to warmly welcome Stephen to EUSA Pharma," said Rolf Stahel, EUSA Pharma's Chairman. "Since its foundation four years ago, EUSA has established itself as a successful transatlantic specialty pharma business, and is now entering its next phase of rapid and profitable growth. Stephen's financial expertise, and history of success in our industry, will prove an important asset as we transition EUSA into one of the most successful companies in its field."

Commenting on his appointment, Stephen A. Stamp said, "Having witnessed EUSA's impressive growth, I am excited to be helping the company achieve its ambitious plans. Having already built a robust commercial infrastructure in the US and Europe, and a wider global distribution network, I believe EUSA is well placed for future success, and I welcome the opportunity to be part of the company's continued rapid development."

About EUSA Pharma

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight marketed products, including Caphosol(R) for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high dose chemotherapy, Erwinase(R) and Kidrolase(R) for the treatment of acute lymphoblastic leukemia, Collatamp(R) G, a surgical implant impregnated with the antibiotic gentamicin, ProstaScint(R) for imaging the extent and spread of prostate cancer and Quadramet(R) for the treatment of pain in patients whose cancer has spread to the bones. EUSA also has several products in late-stage development.

Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, TVM Capital, NeoMed and NovaQuest. Since its foundation, the company has raised over $300 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Limited, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. Key to its rapid growth strategy is the company's established commercial infrastructure in the US, pan-European presence covering over 20 countries and wider distribution network in a further 80 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing, in line with its ambitious target to become the leading specialty company in its areas of therapeutic and geographic focus.

Contacts Bryan Morton Chief Executive EUSA Pharma Tel: +44(0)1865-784255 Rob Budge RJB Communications Tel: +44(0)1865-760969 Mobile: +44(0)7710-741241

Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PDL BioPharma Provides Third Quarter 2010 Revenue Guidance of Approximately $86 Million and Update to its Correspondence With Genentech
2. PharmaNet Development Group Appoints Anthony Maida, Vice President, Clinical Research
3. Reportlinker Adds Advances in Biopharmaceutical Technology in China
4. Access Pharmaceuticals Presents at American Chemical Society Annual Fall Meeting in Boston, MA
5. Archimedes Pharma US Announces New US Headquarters In Bedminster, New Jersey
6. Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
7. NanoSmartâ„¢ Pharmaceuticals, Inc. Receives Patent Allowance for Tumor Targeting Platform Technology
8. PDL BioPharma Announces Retirement of $61.6 Million of 2.75% Convertible Notes due August 2023 for Common Stock
9. K-V Pharmaceutical Company Engages BDO USA, LLP as Independent Registered Accountants
10. CORRECTED: Ampio Pharmaceuticals Announces Completion of Negotiations for Acquisition of DMI BioSciences, Inc.
11. Vanda Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 5, 2010
Post Your Comments:
(Date:11/24/2015)... 2015 Cepheid (NASDAQ: CPHD ) today ... following conference, and invited investors to participate via webcast. ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern Time ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern Time ... New York, NY      Tuesday, December 1, 2015 ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... maintain healthy metabolism. But unless it is bound to proteins, copper is also ... Health (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic study ...
(Date:11/24/2015)... Inc., a worldwide provider of clinical research services headquartered in ... has set a new quarterly earnings record in Q3 of 2015.  ... Q3 of 2014 to Q3 of 2015.   ... the establishment of an Asia-Pacific office to ... and Mexico , with the establishment ...
(Date:11/24/2015)... ... ... The Academy of Model Aeronautics (AMA), led by its Executive Council, has ... Prix, to represent the First–Person View (FPV) racing community. , FPV racing has exploded ... of racing and several new model aviation pilots have joined the community because of ...
Breaking Biology Technology:
(Date:10/29/2015)... YORK , Oct. 29, 2015 ... technology, announced a partnership with 2XU, a global ... to deliver a smart hat with advanced bio-sensing ... and other athletes to monitor key biometrics to ... the strategic partnership, the two companies will bring together ...
(Date:10/27/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), the ... has adopted the Synaptics ® ClearPad ® ... its newest flagship smartphones, the Nexus 5X by LG ... --> --> Synaptics works closely ... collaboration in the joint development of next generation technologies. ...
(Date:10/26/2015)... -- Delta ID Inc., a company focused on bringing secure ... announced its ActiveIRIS® technology powers the iris recognition feature ... NTT DOCOMO, INC in Japan . ... include iris recognition technology, after a very successful introduction ... 2015, world,s first smartphone to have this capability. ...
Breaking Biology News(10 mins):